CAPS Medical (formerly Plasmed), a MEDX Xelerator portfolio company, won first place at a pitch competition at “ITTN,” Israel’s Technology Transfer Organization’s biennial conference, on October 22, 2018. Dr. Jacob Cohen, CAPS Medical’s co-founder, presented their unique technology for selective cancer ablation using cold atmospheric plasma at ITTN’s Life Sciences track. The technology was originally developed jointly by RAMBAM Healthcare Campus and the plasma lab at the Technion, Israel Institute of Technology. It recently received seed funding from MEDX Xelerator.
Dr. Jacob Cohen pitching CAPS Medical at ITTN